LENZ Therapeutics (LENZ) Share-based Compensation (2020 - 2026)
LENZ Therapeutics (LENZ) reported Share-based Compensation of $4.3 million for Q1 2026, up 69.04% year-over-year from $2.6 million in Q1 2025, and up 17.43% on a QoQ basis from $3.7 million in Q4 2025.
LENZ Therapeutics (LENZ) has 7 years of Share-based Compensation data on file, last reported at $4.3 million in Q1 2026.
- Quarterly Share-based Compensation rose 69.04% year-over-year to $4.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.3 million (up 79.49% YoY) and the FY2025 annual result came in at $12.5 million, up 97.12% from the prior year.
- Share-based Compensation advanced to $4.3 million in Q1 2026 per LENZ's latest filing, from $3.7 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $4.3 million in Q1 2026 and bottomed at $142000.0 in Q1 2023.
- The 5-year median for Share-based Compensation is $2.8 million (2023), against an average of $2.5 million.
- The widest annual swing landed in 2023, when Share-based Compensation sank 95.75%; it then jumped 566.9% in 2024.
- Tracing LENZ's Share-based Compensation over 5 years: stood at $3.6 million in 2022, then slumped by 85.7% to $518000.0 in 2023, then jumped by 214.67% to $1.6 million in 2024, then soared by 125.64% to $3.7 million in 2025, then increased by 17.43% to $4.3 million in 2026.
- Per Business Quant, the three latest LENZ Share-based Compensation figures stand at $4.3 million (Q1 2026), $3.7 million (Q4 2025), and $3.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.15 Mn |
| 10 | LENZ Therapeutics | 235.77 Mn | 235.77 Mn | 825,000.00 | 4.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.32 Mn |
| Mar 31, 2026 | 4.32 Mn |
| Dec 31, 2025 | 3.68 Mn |
| Dec 31, 2025 | 3.68 Mn |
| Sep 30, 2025 | 3.47 Mn |
| Sep 30, 2025 | 3.47 Mn |
| Jun 30, 2025 | 2.85 Mn |
| Jun 30, 2025 | 2.85 Mn |
| Mar 31, 2025 | 2.56 Mn |
| Mar 31, 2025 | 2.56 Mn |
| Dec 31, 2024 | 1.63 Mn |
| Dec 31, 2024 | 1.63 Mn |
| Sep 30, 2024 | 2.19 Mn |
| Sep 30, 2024 | 2.19 Mn |
| Jun 30, 2024 | 1.60 Mn |
| Jun 30, 2024 | 1.60 Mn |
| Mar 31, 2024 | 947,000.00 |
| Mar 31, 2024 | 947,000.00 |
| Dec 31, 2023 | 518,000.00 |
| Dec 31, 2023 | 518,000.00 |
| Sep 30, 2023 | 2.16 Mn |
| Sep 30, 2023 | 2.16 Mn |
| Jun 30, 2023 | 2.85 Mn |
| Jun 30, 2023 | 2.85 Mn |
| Mar 31, 2023 | 142,000.00 |
| Mar 31, 2023 | 142,000.00 |
| Dec 31, 2022 | 3.62 Mn |
| Dec 31, 2022 | 3.62 Mn |
| Sep 30, 2022 | 3.21 Mn |
| Sep 30, 2022 | 3.21 Mn |
| Jun 30, 2022 | 3.36 Mn |
| Jun 30, 2022 | 3.36 Mn |
| Mar 31, 2022 | 3.34 Mn |
| Mar 31, 2022 | 3.34 Mn |
| Dec 31, 2021 | 2.45 Mn |
| Dec 31, 2021 | 2.45 Mn |
| Sep 30, 2021 | 2.37 Mn |
| Sep 30, 2021 | 2.37 Mn |
| Jun 30, 2021 | 2.02 Mn |
| Jun 30, 2021 | 2.02 Mn |
| Mar 31, 2021 | 1.03 Mn |
| Mar 31, 2021 | 1.03 Mn |
| Dec 31, 2020 | 140,000.00 |
| Dec 31, 2020 | 140,000.00 |
| Sep 30, 2020 | 36,000.00 |
| Sep 30, 2020 | 36,000.00 |
| Jun 30, 2020 | 1,000.00 |
| Jun 30, 2020 | 1,000.00 |